Dr. Robert Nossa, MD
Dermatology (Dermatology Physician)
Contemporary Dermatology, 3880 Falmouth Rd
Marstons Mills, MA 02648
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,503
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
NJ license MA07221300
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Schweiger Dermatology PC (186 clinicians)
- Contemporary Dermatology LLC (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,503
- Services billed
- 12,443
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 3,327 | 446 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,088 | 763 |
| Destruction of precancer skin growth, 1 growth | 797 | 557 |
| Biopsy of related skin growth, first growth | 548 | 456 |
| Biopsy of related skin growth, each additional growth | 411 | 223 |
| New patient office or other outpatient visit, 30-44 minutes | 293 | 293 |
| Destruction of skin growth, 1-14 growths | 172 | 151 |
| Destruction of precancer skin growth, 15 or more growths | 169 | 133 |
| Established patient office or other outpatient visit, 10-19 minutes | 143 | 126 |
| Established patient office or other outpatient visit, 30-39 minutes | 65 | 48 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 194 payments worth $3,372 in total to this clinician.
| AbbVie Inc. | $487 |
|---|---|
| Novartis Pharmaceuticals Corporation | $475 |
| Janssen Biotech, Inc. | $431 |
| Leo Pharma Inc. | $234 |
| Sun Pharmaceutical Industries Inc. | $205 |
| E.r. Squibb & Sons, L.l.c. | $200 |
| UCB, Inc. | $189 |
| Botanix Sb Inc | $184 |
| Food and Beverage | $3,268 |
|---|---|
| Education | $105 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Apr 3, 2025 | Education TREMFYA · Immunology · in-kind | $94.99 |
| AbbVie Inc. May 13, 2025 | Education SKYRIZI · IMMUNOLOGY · in-kind | $9.65 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $54,874 in research payments for these studies, mostly to the institutions running them.
- A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
AbbVie Inc. · Active, not recruiting · NCT06118411 - M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up)
AbbVie Inc. - Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Sun Pharmaceutical Industries Inc. - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
AbbVie Inc. · Active, not recruiting · NCT05889182 - A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
UCB SA · Completed · NCT04901195
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.